Two meta-analyses have demonstrated decreased adiponectin levels in obese endometrial cancer patients compared to non-obese endometrial cancer patients [18, 20], from which we may infer that adiponectin, which has an anti-inflammatory effect, reduces the risk of endometrial cancer. The gene discussed is ADIPOQ; the disease is endometrial cancer.